Abstract: This invention relates to a method for the treatment and prevention of migraine and affective illness by administering a therapeutically effective amount of the valproic acid analog 2-n-propyl-4-hexynoic acid. The compound 2-n-propyl-4-hexynoic acid is an effective anti-migraine and anti-affective illness drug with greatly reduced adverse effects including neurotoxicity and teratogenic potential compared to valproic acid. This invention thus provides an improved method for treating and preventing migraine and affective illness.

Abstract: Benzo[b]quinolizidine and benzo[f]indolizidine derivatives are provided which are useful for the treatment of Alzheimer's disease, senile dementia or other conditions characterized by memory loss. Pharmaceutical compositions containing these compounds, and methods for their use, are also provided.

Abstract: Neurotrophic and antiproliferative compounds related to the antiepileptic drug valproate are provided. These compounds are useful for promoting neuronal function as in neurodegenerative disorders and for treating neoplastic disease.

Abstract: The subject invention relates a method for the production of monoclonal antibodies. The method utilizes an immunized germfree animal. The invention also provides methods for the use of such monoclonal antibodies, and polyclonal antibodies derived from an immunized germfree animal, for in vitro and in vivo clinical diagnostics and therapeutics. Also, the subject invention provides a fibrin-specific monoclonal antibody.

Abstract: Neurotrophic and antiproliferative compounds related to the antiepileptic drug valproate are provided. These compounds are useful for promoting neuronal function as in neurodegenerative disorders and for treating neoplastic disease.

Abstract: This invention relates to a method for the treatment and prevention of migraine and affective illness by administering a therapeutically effective amount of the valproic acid analog 2-n-propyl-4-hexynoic acid. The compound 2-n-propyl-4-hexynoic acid is an effective anti-migraine and anti-affective illness drug with greatly reduced adverse effects including neurotoxicity and teratogenic potential compared to valproic acid. This invention thus provides an improved method for treating and preventing migraine and affective illness.

Abstract: The subject invention relates a method for the production of monoclonal antibodies. The method utilizes an immunized germfree animal. The invention also provides methods for the use of such monoclonal antibodies, and polyclonal antibodies derived from an immunized germfree animal, for in vitro and in vivo clinical diagnostics and therapeutics. Also, the subject invention provides a fibrin-specific monoclonal antibody.

Abstract: Novel methods for radiolabeling sulfhydryl group-bearing biomolecules, novel compositions useful for radiolabeling sulfhydryl group-bearing biomolecules, kits comprising such novel compositions and methods for imaging mammalian, preferably human, tissue employing radiolabelled biomolecules are described. The methods, compositions and kits of the present invention are useful for labeling sulfhydryl group-bearing biomolecules such as whole molecule proteins, protein fragments or peptides, in particular, monoclonal or polyclonal antibodies, and especially, antifibrin MH1 monoclonal antibody.

Abstract: The subject invention relates a method for the production of monoclonal antibodies. The method utilizes an immunized germfree animal. The invention also provides methods for the use of such monoclonal antibodies, and polyclonal antibodies derived from an immunized germfree animal, for in vitro and in vivo clinical diagnostics and therapeutics. Also, the subject invention provides a fibrin-specific monoclonal antibody.

Abstract: An in vitro immunoassay to detect and quantitate soluble crosslinked and non-crosslinked DesAABB fibrin polymers in a sample from a subject. The assay can be used to support a diagnosis of, to evaluate, and to monitor, in a mammalian subject, a thrombotic event, including, but not limited to, myocardial infarction, pulmonary embolism, stroke and deep vein thrombosis.

Abstract: The subject invention relates a method for the production of monoclonal antibodies. The method utilizes an immunized germfree animal. The invention also provides methods for the use of such monoclonal antibodies, and polyclonal antibodies derived from an immunized germfree animal, for in vitro and in vivo clinical diagnostics and therapeutics. Also, the subject invention provides a fibrin-specific monoclonal antibody.

Abstract: A method of obtaining lymphocytes making a highly specific antibody by immunizing an antigen-free mouse and removing the blood, lymph nodes or spleen from the immunized mouse. Alternatively, a method of making highly specific poly clonal antibodies by immunizing an antigen-free mouse and removing serum from the mouse. Specific embodiments include multiple immunizations, immunizations with dissolved antigens, and immunizations with adjuvants.

Abstract: Neurotrophic and antiproliferative compounds related to the antiepileptic drug valproate are provided. These compounds are useful for promoting neuronal function as in neurodegenerative disorders and for treating neoplastic disease.

Abstract: Methods for the use of a fibrin-specific antibody for in vivo inhibition of thrombus formation. Pharmaceutical compositions, as well as kits, for use in such methods are also provided.

Abstract: An in vitro immunoassay to detect and quantitate soluble crosslinked and non-crosslinked DesAABB fibrin polymers in a sample from a subject. The assay can be used to support a diagnosis of, to evaluate, and to monitor, in a mammalian subject, a thrombotic event, including, but not limited to, myocardial infarction, pulmonary embolism, stroke and deep vein thrombosis.

Abstract: A laser capable of generating polychromatic or white light radiation is realized by employing dispersive and reflecting elements as the ends of a simple laser resonator cavity. The dispersive element either solely or in combination with an intracavity lens is arranged such that each wavelength component of the white light radiation is amplified by a different portion of the active medium. More specifically, forced oscillation or positive feedback for each wavelength component is achieved by operating a diffraction grating in an auto-collimation configuration or through the use of a distributed bragg reflector having a spatially varying index of refraction.

Abstract: A laser capable of generating polychromatic or whim light radiation is realized by employing a diffraction grating and reflecting element as the ends of a simple laser resonator cavity. The dispersive element either solely or in combination with an intracavity lens is arranged such that each wavelength component of the white light radiation is amplified by a different portion of the active medium. Forced oscillation or positive feedback for each wavelength component is achieved by operating the diffraction grating in an auto-collimation configuration.

Abstract: A polychromatic or white light laser arrangement for changing the dimensions of the pumped portions of the active medium is realized by employing an optical divider for dividing the pump radiation into at least two beamlets, and one or more lenses for focusing the pump radiation onto the active medium. In one preferred embodiment, the optical divider includes a system of mirrors and lenses, or an acousto-optic deflector.

Abstract: A controlled spectrum generation laser arrangement achieving greater uniformity in the optical power spectral distribution is realized by employing a matching plate that conforms the boundary interface of the active medium with the shape of the focal surface of the pump radiation. The matching plate ensures that for any portion of the active medium the pump radiation is focused at its boundary interface so as to achieve a uniform pump beam intensity.

Abstract: The present invention is directed to genetically engineered expression systems which encode a recombinant Hepatitis A virus (HAV) proteins capable of forming capsid particles. By way of example baculovirus vectors were utilized in order to express recombinant HAV proteins. The recombinant baculoviruses of the invention are formed by replacing regions of the polyhedrin structural gene coding sequences with HAV DNA by recombinant DNA techniques. Additionally, the polyhedrin transcriptional initiation site is altered in these recombinant baculoviruses such that only HAV proteins and not polyhedrin protein sequences are expressed from the polyhedrin promoter. The recombinant HAV capsid particles produced in accordance with the present invention can be particularly useful as vaccines.